1Roth JA,Atkinso EN,Fossella F,et al. Lon-term follow-up of patients enrolled in a randomized trial comparing periopertive chemot herapy and surgery with surgery alone in resectable stage ⅢA nonsmall cell lung cancre. Lung cancer, 1998,21:1 ～ 6.
2osell R,Gomez-Codina J,Camps C,et al. Preresectional chemotherapy in stage ⅢA non-small cell lung cancer:a 7-year assessment of a randomized controlled trial. Lung Cancer, 1999,26: 7 ～ 14.
5Socinski MA,Kies M,Schell MJ,et al . Duration of therapy in stage ⅢB non -small cell lung cancer(NSCLC) :a multi-institutional phas IItrial,Proc Am soc clin Oncol,2001 ,20:309A.
6Smith IE,Brien M. E. R,Talbot DC,et al . Duration of Chemotherapy in Aduvanced Non-Small-Cell Lung Cancer:A Randomized Teial of Three Versus Six Courses of Mitimycin, Vinblastine, and Cisplatin. J Clin Oncol, 2001,19 (3): 1336 ～ 1343.
5Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Croup (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys,1995,31 (5) :1341 - 1346.
6Sause W,Kolesar P, Taylor SIV,et al. Final results of phase Ⅲ trial in regionally advanced unresectable non - small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group and Southwest Oncology Group. Chest,2000,117(2)358 -364.
